您现在的位置是：首页>权威专家> 乳腺癌

Lawrence Flaherty M.D.

Lawrence Flaherty M.D.

所在科室：外科

就职医院：Karmanos cancer center

医生擅长：

在线咨询医学顾问 电话热线：400-666-7998

医生介绍

 ·         Gender

·         Male

·         Multidisciplinary Team(s)

·         Breast Cancer 
Melanoma/Skin 

·         Department/Research Program(s)

·         Department of Oncology 

·         Cancer Type(s)

·         Breast cancer 
Melanoma 

·         Contact Info

·         Email:
flaherty@karmanos.org

·         Education

·         Fellowship
Medical oncology - Mt. Sinai Hospital, Milwaukee, WI
Fellowship
Medical oncology - Hospital of the University of Pennsylvania, Philadelphia, PA
Medical School
St. Louis University School of Medicine
Residency
Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
Residency
Chief Medical Resident - Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
Residency
Internal Medicine, Hematology/Oncology

·         Professional Memberships/Associations

·         American Society of Clinical Oncology 
Southwest oncology Group 
American College of Physicians 
Board of Directors, Michigan Society of Hematology and Oncology 

·         Board Certifications

·         American Board of Internal Medicine
American Board of Oncology
American Board of Hematology

·         Clinical Interests

·         Medical Oncologist 

·         Research Interests

·         Multidisciplinary care of patients with breast cancer and melanoma. Clinical research trials. 

·         Profile

·         Lawrence Flaherty's research interests, funded by the National Cancer Institute and several pharmaceutical studies, focus on the treatment of malignant melanomas, breast cancer and other solid tumors with a variety of experimental and traditional cancer therapeutics including Interleukin-2. Flaherty is on the board of the Southwest oncology Group (SWOG) and a member of the ASCO Education Committee and a member of the NCI-H Cooperative group study section. Flaherty has received numerous awards including the Barbara Ann Karmanos Cancer Institute's President's Achievement Award in Clinical Service for 2000 and being listed for several years in the Best Doctors in America. He has authored more than 70 articles in peer-reviewed journals and written four book chapters, and has reviewed for numerous journals. Flaherty received his B.S. (1974) from the University of Notre Dame and his M.D. (1978) from the St. Louis University School of Medicine (St. Louis, Missouri). He completed an internship (1979) and residency (1981) and was the Chief Medical Resident (1982) at the Medical College of Wisconsin Affiliated Hospitals in Milwaukee, Wisconsin. He completed fellowships in Hematology-oncology at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (1986).

·         Awards

·         Best Doctors in America
Top Physicians in Detroit
2000 Karmanos Cancer Center, Clinical Excellence Award
2000 Karmanos Cancer Center – President’s Achievement Award in Clinical Service
Voted one of Best Doctors Inc. 2011-2012 Best Doctors of the Year

·         Publications

·         Phase III Trial Comparing Concurrent Biochemotherapy with Cisplatin, Vinblastine, Darcarbazine, Interleuken-2, and Interferon Alfa-2b with Cisplatin, Vinblastine, and Darcarbazine Alone in Patients with metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative oncology Group. J Clin oncol 26:5748-5754, 2008. PMID: 19001327. Authors: Atkins, M.B., Hsu, J., Lee S., Cohen G.I., Flaherty, L.E., Sosman, J.A., Sondak V.K., Kirwood J.M.
A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Kin): A Southwest oncology Group Study (S0331). Am J Clin oncol 2009 Dec 16 [Epub ahead of print]. PMID: 20019577. Authors: Samlowski W.E., Moon J., Tuthill R.J., Heinrich M.C., Balzer-Haas N.S., Merl S.A., Deconti R.C., Thompson J.A., Witter M.T., Flaherty L.E., Sondak V.K..
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest oncology Group S0508. Cancer 116(2)424-31, 2010. PMID: 19918923. Authors: Clark J.I., Moon J., Hutchins L.F., Sosman J.A., Kast W.M, Da Silva D.M., Liu P.Y., Thompson J.A., Flaherty L.E., Sondak V.K.
A Study of Paclitaxel, Carboplatin, and Bortezomib in The Treatment of metastatic Malignant Melanoma: A Phase 2 Consortium Study. Cancer 2010 Jul 15; 116(14):3463-8. PMID: 20564112. Authors: Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN, Erlichman C.
A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin). Am J Clin oncol 33(5):495-499, 2010. PMID 20019577. Authors: Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Palzer-Haas NS, Merl SA, DeConti RC, Thompson JA, Witter MT, Flaherty LE, Sondak VK.

  

相关报道资讯

视频科普

【3月12日】肿瘤患者怎样避免人财两空？
【3月12日】肿瘤患者怎样避免人财两空？

简介：... 更多»

肿瘤临床试验患者真实采访（下）患者谈：临床试验是小白鼠吗？
肿瘤临床试验患者真实采访（下）患者谈：临床试验是小白鼠吗？

简介：... 更多»

肿瘤临床试验患者真实采访（上）临床试验带来的希望
肿瘤临床试验患者真实采访（上）临床试验带来的希望

简介：... 更多»

胃癌IV期伴有肝脏及肝胃间隙淋巴结转移患者赴日就医
胃癌IV期伴有肝脏及肝胃间隙淋巴结转移患者赴日就医

简介： 胃癌IV期伴有肝脏及肝胃间隙淋巴结转移，国内无标准方案，会诊得知这里胃癌5年生存率相比要高。习惯了家里的医院，还真不适应... 更多»

大肠癌伴肝转移患者赴日就医
大肠癌伴肝转移患者赴日就医

简介：大肠癌伴肝转移，本想国内治疗，但通过日ben癌研有明医院在线会诊，家人支持来院手术。非常顺利4小时完成切除和淋巴结清扫，第二... 更多»

胶质母细胞瘤和髓母细胞瘤患者赴日就医
胶质母细胞瘤和髓母细胞瘤患者赴日就医

简介： 你经历过绝望到希望吗？在国内先后被诊断为胶质母细胞瘤和髓母细胞瘤的患者。术后只做了脑部放疗，复发了。最后参加了日ben国... 更多»

肝癌患者日本国际就医案例
肝癌患者日本国际就医案例

简介： 肝癌，多年前在日ben癌研有明病院做的手术，这次来复查，结果很满意，但是还需3个月后再次复查，6月份再来，明日回国，感谢帮... 更多»

癌症患者的新方案来了！数十位国际专家带先进技术助力国内癌症患者
癌症患者的新方案来了！数十位国际专家带先进技术助力国内癌症患者

简介：癌症患者的新方案来了！数十位国际专家带先进技术助力国内癌症患者... 更多»

在线预约

绿色快速预约通道

Lawrence Flaherty M.D.

请正确填写预约人和联系人等信息，提交需求成功后，请保持联系电话畅通，客服会在48小时内与您联系确认信息。客服热线：400-666-7998

资讯 查看

全球找新药第十五期|​"​370万一针"的TIL疗法堪称天价!国研TIL疗法启动在线招募 12.24 愈见大"CAR"|"抗癌神器"CAR-T是什么?如何治疗多发性骨髓瘤 确诊肠癌后先别着急切!看看日本的高水平精密手术是如何做的 国内无药可用≠绝境!揭秘癌症患者赴美就医流程与优势,重拾希望之光 14：30 愈见大"CAR"|"抗癌神器"CAR-T是什么?如何治疗多发性骨髓瘤 15：00 直播预告|肿瘤类器官精准个体化药敏检测 愈见大"CAR"|"抗癌神器"CAR-T是什么?如何治疗多发性骨髓瘤 直播预告|为什么越来越多的中国癌症患者选择赴日治疗

推荐专家

医院 全部医院

Lawrence Flaherty M.D.

Karmanos cancer center 外科

擅长

简介

 ·         Gender

·         Male

·         Multidisciplinary Team(s)

·         Breast Cancer 
Melanoma/Skin 

·         Department/Research Program(s)

·         Department of Oncology 

·         Cancer Type(s)

·         Breast cancer 
Melanoma 

·         Contact Info

·         Email:
flaherty@karmanos.org

·         Education

·         Fellowship
Medical oncology - Mt. Sinai Hospital, Milwaukee, WI
Fellowship
Medical oncology - Hospital of the University of Pennsylvania, Philadelphia, PA
Medical School
St. Louis University School of Medicine
Residency
Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
Residency
Chief Medical Resident - Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
Residency
Internal Medicine, Hematology/Oncology

·         Professional Memberships/Associations

·         American Society of Clinical Oncology 
Southwest oncology Group 
American College of Physicians 
Board of Directors, Michigan Society of Hematology and Oncology 

·         Board Certifications

·         American Board of Internal Medicine
American Board of Oncology
American Board of Hematology

·         Clinical Interests

·         Medical Oncologist 

·         Research Interests

·         Multidisciplinary care of patients with breast cancer and melanoma. Clinical research trials. 

·         Profile

·         Lawrence Flaherty's research interests, funded by the National Cancer Institute and several pharmaceutical studies, focus on the treatment of malignant melanomas, breast cancer and other solid tumors with a variety of experimental and traditional cancer therapeutics including Interleukin-2. Flaherty is on the board of the Southwest oncology Group (SWOG) and a member of the ASCO Education Committee and a member of the NCI-H Cooperative group study section. Flaherty has received numerous awards including the Barbara Ann Karmanos Cancer Institute's President's Achievement Award in Clinical Service for 2000 and being listed for several years in the Best Doctors in America. He has authored more than 70 articles in peer-reviewed journals and written four book chapters, and has reviewed for numerous journals. Flaherty received his B.S. (1974) from the University of Notre Dame and his M.D. (1978) from the St. Louis University School of Medicine (St. Louis, Missouri). He completed an internship (1979) and residency (1981) and was the Chief Medical Resident (1982) at the Medical College of Wisconsin Affiliated Hospitals in Milwaukee, Wisconsin. He completed fellowships in Hematology-oncology at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (1986).

·         Awards

·         Best Doctors in America
Top Physicians in Detroit
2000 Karmanos Cancer Center, Clinical Excellence Award
2000 Karmanos Cancer Center – President’s Achievement Award in Clinical Service
Voted one of Best Doctors Inc. 2011-2012 Best Doctors of the Year

·         Publications

·         Phase III Trial Comparing Concurrent Biochemotherapy with Cisplatin, Vinblastine, Darcarbazine, Interleuken-2, and Interferon Alfa-2b with Cisplatin, Vinblastine, and Darcarbazine Alone in Patients with metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative oncology Group. J Clin oncol 26:5748-5754, 2008. PMID: 19001327. Authors: Atkins, M.B., Hsu, J., Lee S., Cohen G.I., Flaherty, L.E., Sosman, J.A., Sondak V.K., Kirwood J.M.
A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Kin): A Southwest oncology Group Study (S0331). Am J Clin oncol 2009 Dec 16 [Epub ahead of print]. PMID: 20019577. Authors: Samlowski W.E., Moon J., Tuthill R.J., Heinrich M.C., Balzer-Haas N.S., Merl S.A., Deconti R.C., Thompson J.A., Witter M.T., Flaherty L.E., Sondak V.K..
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest oncology Group S0508. Cancer 116(2)424-31, 2010. PMID: 19918923. Authors: Clark J.I., Moon J., Hutchins L.F., Sosman J.A., Kast W.M, Da Silva D.M., Liu P.Y., Thompson J.A., Flaherty L.E., Sondak V.K.
A Study of Paclitaxel, Carboplatin, and Bortezomib in The Treatment of metastatic Malignant Melanoma: A Phase 2 Consortium Study. Cancer 2010 Jul 15; 116(14):3463-8. PMID: 20564112. Authors: Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN, Erlichman C.
A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin). Am J Clin oncol 33(5):495-499, 2010. PMID 20019577. Authors: Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Palzer-Haas NS, Merl SA, DeConti RC, Thompson JA, Witter MT, Flaherty LE, Sondak VK.

  

TA的文章视频

  • 在线咨询
  • 病友群
  • 联系电话
    咨询电话400-6667998
  • 返回顶部